RxDoctor Payments Data

Catherine Dalyai

Adult Health · Philadelphia, PANPI 1316233042

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 34 payments — averaging $57.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$905
  • Boston Scientific$166
  • Imperative Care, Inc$141
  • Penumbra, Inc.$125
  • Almatica Pharma LLC$99
  • Virtus Pharmaceuticals LLC$89
  • plus $434 from 13 others

What the payments were for

  • Travel & lodging$62632%
  • Food & beverage$1,33468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,959 in reported general payments places this provider in the 75th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,744
Medicare patients
18
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl47$39,993
Nucynta ErTapentadol Hcl11$26,691
Hydrocodone Bitartrate ErHydrocodone Bitartrate12$5,349
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen117$2,465
Pregabalin59$2,314
Gabapentin69$895
Acetaminophen-CodeineAcetaminophen With Codeine13$330
Baclofen35$318
Cyclobenzaprine Hcl34$217
Duloxetine Hcl18$183
Oxycodone Hcl12$155
Tramadol Hcl57$153
Meloxicam21$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er$63$66,68458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →